Health-related quality of life in primary immunodeficiencies : Impact of delayed diagnosis and treatment burden

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 236(2022) vom: 02. März, Seite 108931
1. Verfasser: Anderson, John T (VerfasserIn)
Weitere Verfasser: Cowan, Juthaporn, Condino-Neto, Antonio, Levy, Donald, Prusty, Subhransu
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Review Diagnostic delay IgRT Primary antibody deficiency Primary immunodeficiency QOL Treatment
LEADER 01000caa a22002652c 4500
001 NLM335982557
003 DE-627
005 20250302224254.0
007 cr uuu---uuuuu
008 231225s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2022.108931  |2 doi 
028 5 2 |a pubmed25n1119.xml 
035 |a (DE-627)NLM335982557 
035 |a (NLM)35063670 
035 |a (PII)S1521-6616(22)00011-0 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Anderson, John T  |e verfasserin  |4 aut 
245 1 0 |a Health-related quality of life in primary immunodeficiencies  |b Impact of delayed diagnosis and treatment burden 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 06.05.2022 
500 |a Date Revised 06.05.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. 
520 |a Accurate and timely diagnosis of primary immunodeficiencies (PID) is an ongoing effort. Individuals with PID can be severely impacted by their disease and many experience chronic complications, treatment burden, and reduced quality of life (QoL). This review focuses on the impact of delayed diagnosis and treatment burden on patient QoL and outcomes. Adults tend to experience longer delays in diagnosis than pediatric populations. The median diagnostic delay has reduced over recent decades, but remains high for some antibody deficiency variants, such as common variable immunodeficiency. The largest burden impacting QoL tends to be poorly controlled disease and persistent chronic conditions rather than treatment burden. Hospitalization, physician/emergency room visits, and bronchiectasis were the most expensive PID complications prior to diagnosis and cost analyses estimate cost reductions once appropriate treatment is initiated. A combination of poor awareness, lack of infrastructure, and resources supporting national registries play a major role in delayed diagnosis 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Review 
650 4 |a Diagnostic delay 
650 4 |a IgRT 
650 4 |a Primary antibody deficiency 
650 4 |a Primary immunodeficiency 
650 4 |a QOL 
650 4 |a Treatment 
700 1 |a Cowan, Juthaporn  |e verfasserin  |4 aut 
700 1 |a Condino-Neto, Antonio  |e verfasserin  |4 aut 
700 1 |a Levy, Donald  |e verfasserin  |4 aut 
700 1 |a Prusty, Subhransu  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 236(2022) vom: 02. März, Seite 108931  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:236  |g year:2022  |g day:02  |g month:03  |g pages:108931 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2022.108931  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 236  |j 2022  |b 02  |c 03  |h 108931